Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 51

1.

Metabolic origins and clinical significance of LDL heterogeneity.

Berneis KK, Krauss RM.

J Lipid Res. 2002 Sep;43(9):1363-79. Review.

PMID:
12235168
[PubMed - indexed for MEDLINE]
Free Article
2.

Clinical relevance of the biochemical, metabolic, and genetic factors that influence low-density lipoprotein heterogeneity.

Kwiterovich PO Jr.

Am J Cardiol. 2002 Oct 17;90(8A):30i-47i. Review.

PMID:
12419479
[PubMed - indexed for MEDLINE]
3.

Relevance of hepatic lipase to the metabolism of triacylglycerol-rich lipoproteins.

Zambon A, Bertocco S, Vitturi N, Polentarutti V, Vianello D, Crepaldi G.

Biochem Soc Trans. 2003 Oct;31(Pt 5):1070-4. Review.

PMID:
14505482
[PubMed - indexed for MEDLINE]
4.

Atherogenic, dense low-density lipoproteins. Pathophysiology and new therapeutic approaches.

Chapman MJ, Guérin M, Bruckert E.

Eur Heart J. 1998 Feb;19 Suppl A:A24-30. Review.

PMID:
9519339
[PubMed - indexed for MEDLINE]
5.

Dense low density lipoproteins and coronary artery disease.

Krauss RM.

Am J Cardiol. 1995 Feb 23;75(6):53B-57B. Review.

PMID:
7863975
[PubMed - indexed for MEDLINE]
6.

The significance of low-density-lipoproteins size in vascular diseases.

Rizzo M, Berneis K, Corrado E, Novo S.

Int Angiol. 2006 Mar;25(1):4-9. Review.

PMID:
16520717
[PubMed - indexed for MEDLINE]
Free Article
7.

Role of fibric acid derivatives in the management of risk factors for coronary heart disease.

Després JP, Lemieux I, Robins SJ.

Drugs. 2004;64(19):2177-98. Review.

PMID:
15456334
[PubMed - indexed for MEDLINE]
8.

Should we measure routinely the LDL peak particle size?

Rizzo M, Berneis K.

Int J Cardiol. 2006 Feb 15;107(2):166-70. Review.

PMID:
16412793
[PubMed - indexed for MEDLINE]
9.

Triacylglycerol-rich lipoproteins and the generation of small, dense low-density lipoprotein.

Packard CJ.

Biochem Soc Trans. 2003 Oct;31(Pt 5):1066-9. Review.

PMID:
14505481
[PubMed - indexed for MEDLINE]
10.

Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.

Nesto RW.

Am J Cardiovasc Drugs. 2005;5(6):379-87. Review.

PMID:
16259526
[PubMed - indexed for MEDLINE]
11.

Statins for treatment of dyslipidemia in chronic kidney disease.

Shurraw S, Tonelli M.

Perit Dial Int. 2006 Sep-Oct;26(5):523-39. Review.

PMID:
16973506
[PubMed - indexed for MEDLINE]
Free Article
12.

Atherogenic lipoprotein particles in atherosclerosis.

Carmena R, Duriez P, Fruchart JC.

Circulation. 2004 Jun 15;109(23 Suppl 1):III2-7. Review.

PMID:
15198959
[PubMed - indexed for MEDLINE]
Free Article
13.

The physiology of lipoproteins.

Tulenko TN, Sumner AE.

J Nucl Cardiol. 2002 Nov-Dec;9(6):638-49. Review.

PMID:
12466789
[PubMed - indexed for MEDLINE]
14.

[Atherogenicity of low-density lipoproteins (LDL). A problem of quantity or quality?].

Dejager S, Turpin G.

Presse Med. 1995 Dec 9;24(38):1772-6. Review. French.

PMID:
8545426
[PubMed - indexed for MEDLINE]
15.

Phospholipase A2 and small, dense low-density lipoprotein.

Hurt-Camejo E, Camejo G, Sartipy P.

Curr Opin Lipidol. 2000 Oct;11(5):465-71. Review.

PMID:
11048889
[PubMed - indexed for MEDLINE]
16.

Lipoprotein abnormalities and their consequences for patients with type 2 diabetes.

Krentz AJ.

Diabetes Obes Metab. 2003 Nov;5 Suppl 1:S19-27. Review.

PMID:
14984018
[PubMed - indexed for MEDLINE]
17.

Lipoprotein atherogenicity: an overview of current mechanisms.

Griffin BA.

Proc Nutr Soc. 1999 Feb;58(1):163-9. Review.

PMID:
10343354
[PubMed - indexed for MEDLINE]
18.

Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia.

Le Goff W, Guerin M, Chapman MJ.

Pharmacol Ther. 2004 Jan;101(1):17-38. Review.

PMID:
14729390
[PubMed - indexed for MEDLINE]
19.

The role of non-LDL:non-HDL particles in atherosclerosis.

Segrest JP.

Curr Diab Rep. 2002 Jun;2(3):282-8. Review.

PMID:
12643186
[PubMed - indexed for MEDLINE]
20.

Relations between metabolic syndrome, oxidative stress and inflammation and cardiovascular disease.

Holvoet P.

Verh K Acad Geneeskd Belg. 2008;70(3):193-219. Review.

PMID:
18669160
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk